NJBIZ, New Jersey’s leading business journal, provides 24/7 business news coverage and events honoring top business professionals ...

X4 Pharmaceuticals, a Cambridge startup with deep ties to Genzyme, has laid out its clinical development plans for its small molecule CXCR4 antagonists that help rev up the immune system and ...

Sanofi-Aventis is buying specialty drugmaker Genzyme for $20.1 billion, the latest example of a beleaguered pharmaceutical company snapping up high-priced biotech drugs to offset dwindling sales ...

Sanofi Genzyme will partner with Alnylam Pharmaceuticals to develop one of its drug candidates, while taking a pass on another, Alnylam said today. The specialty care global business unit of ...

The Genzyme-SangStat announcement came six weeks after Idec Pharmaceuticals Corp. agreed to spend $6.4 billion to acquire rival Biogen Inc. Idec, based in San Diego, and Cambridge-based Biogen ...

Genzyme is a leading bio-pharmaceutical company based in Cambridge, Massachusetts. Its products address rare diseases, kidney disease, orthopedics, cancer, transplant and immune diseases, ...

Genzyme Corp. said it would spend $325 million up front in a licensing and investment pact with Isis Pharmaceuticals Inc., securing partial rights to a promising cholesterol-lowering drug that ...

PARIS -- French drug maker Sanofi-Aventis SA has agreed to buy Genzyme Corp. in a sweetened all-cash $20.1 billion deal that ends months of corporate haggling and positions Sanofi at the forefront ...

Cambridge-based Genzyme Corp., which has operations in Central Massachusetts, has completed the sale of its pharmaceutical intermediates business to Germany's International Chemical Investors ...

French pharmaceutical firm Sanofi-Aventis threatened to take control of Genzyme's board if it doesn't approve an $18.5 billion hostile takeover offer.